

CORTENDO PLC

Cortendo plc Changes Name to Strongbridge Biopharma plc

Dublin, Ireland and Treviso, Pa., USA – September 4, 2015 – Cortendo plc announced today that the Company has changed its name to Strongbridge Biopharma plc.

Strongbridge Biopharma will become effective immediately and the new logo and corporate branding elements will be rolled out in the near future.

Under the new corporate name, Strongbridge Biopharma will remain committed to building a biopharmaceutical company focused on the development, in-licensing, acquisition and eventual commercialization of complementary product candidates across multiple franchises that target rare diseases.

About Strongbridge Biopharma

Following the settlement of its exchange offer to acquire any and all issued ordinary shares of Cortendo AB, Strongbridge Biopharma (formerly known as Cortendo plc) will become the new parent company of the Cortendo group. The group's strategic focus is to build a biopharmaceutical company focused on the development, in-licensing, acquisition and eventual commercialization of complementary product candidates across multiple franchises that target rare diseases. The group's lead product candidate, COR-003 (levoketoconazole), is a cortisol inhibitor that is currently being studied in the global Phase 3 trial for the treatment of endogenous Cushing's syndrome. COR-003 has received orphan designation from both the European Medicines Agency and the U.S. Food and Drug Administration. The group recently expanded its rare endocrine disease franchise with the completion of transactions for two Phase 2 product candidates: COR-004, a novel second-generation antisense compound, which is in clinical development for acromegaly and designed to block the synthesis of growth hormone receptor (GHR) thereby reducing levels of insulin-like growth factor-1 (IGF-1) in the blood; and COR-005, a next-generation somatostatin analog (SSA) with a unique receptor affinity profile, being investigated for the treatment of acromegaly, with potential additional applications in Cushing's disease and neuroendocrine tumors. The group's intent is to independently commercialize its rare endocrine assets in key global markets.

Strongbridge Biopharma Forward Looking Statements

This press release contains forward-looking statements concerning Strongbridge Biopharma that involve a number of risks and uncertainties. All statements other than statements of historical facts included in this press release, including, without limitation, statements regarding Strongbridge Biopharma's strategy, anticipated investments, financial position, outcomes of product development efforts and objectives of management for future operations, may be deemed to be forward-looking statements. These forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause Strongbridge Biopharma's actual results, performance or achievements or industry results to be materially different from

those contemplated, projected, forecasted, estimated or budgeted, whether expressed or implied, by these forward-looking statements. Given these risks and uncertainties, investors should not place any undue reliance on forward-looking statements as a prediction of actual results. None of these forward-looking statements constitutes a guarantee of the future occurrence of such facts and data or of actual results. These statements are based on data, assumptions and estimates that Strongbridge Biopharma believes are reasonable. The forward-looking statements contained in this document are made only as of the date hereof. Strongbridge Biopharma expressly disclaims any obligation or undertaking to release publicly any updates of any forward-looking statements contained in this press release to reflect any change in its actual results, assumptions, expectations or any change in events, factors, conditions or circumstances on which any forward-looking statement contained in this press release is based.

Contacts:

Corporate and Media Relations

Elixir Health Public Relations

Lindsay Rocco

+1 862-596-1304

lrocco@elixirhealthpr.com

Investor Relations

ICR Inc.

Stephanie Carrington

+1 646-277-1282

Stephanie.Carrington@icrinc.com

Ireland

Arthur Cox Building

Earlsfort Terrace

Dublin 2

Ireland

USA

900 Northbrook Drive

Suite 200

Trevoze, PA 19053

Tel. +1 610-254-9200

Fax. +1 215-355-7389